Crestline Management, LP Catalyst Pharmaceuticals, Inc. Transaction History

Crestline Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$2.81 - $3.78 $1.37 Million - $1.85 Million	-488,243 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.26 - $3.84 $93,882 - $159,517	41,541 Added 9.3%	488,243 $1.52 Million
Q1 2018 May 15, 2018	BUY	$2.39 - $4.01 $429,220 - $720,155	179,590 Added 67.23%	446,702 $1.07 Million
Q4 2017 Feb 14, 2018	BUY	$2.51 - $4.4 $110,673 - $194,009	44,093 Added 19.77%	267,112 $1.04 Million
Q3 2017 Nov 14, 2017	BUY	$2.4 - $2.94 $535,245 - $655,675	223,019	223,019 $562,000

348

98.4M

13.4K

11.7K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.54B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.